• The Only Non Profit Organization Founded by Rosaceans [rosacea sufferers] for Rosaceans

    Welcome to the RRDi official web site.

    The Rosacea Research & Development Institute [RRDi] is the first 501 (c) (3) non profit corporation established June 7, 2004 in the State of Hawaii, USA for the purpose of finding a cure for rosacea, researching rosacea, and to form a patient advocacy organization established by volunteer rosaceans for rosacea sufferers. State of Hawaii Certificate of Good Standing.

    Our 2016 Rosacea Survey is completed.  You may review our comprehensive list of our education grants

    What is Rosacea?

    Rosacea is a chronic and sometimes progressive disorder of the face, characterized by some or all of the following symptoms:

    Extremely sensitive skin, blushing, flushing, permanent redness, burning, stinging, swelling, papules, pustules, broken red capillary veins, red gritty eyes (which can lead to visual disturbances) and in more advanced cases, a disfiguring bulbous nose. Men and women of all ages can be affected, with over 74 million estimated sufferers of Rosacea worldwide. For more info click here.

    "Rosacea is a multifactorial, hyper-reactivity, vascular and neural based disease with a broad range of facial manifestations where normal vasodilation is greater and more persistent and involves an autoimmune component where microscopic amounts of extravasated plasma induce localized dermal inflammation where repeated external triggers lead vasodilation, telangiectasias, redness with eventual fibrosis and hypertrophic scarring of the dermis." Sandra Cremers, M.D., F.A.C.S., RRDi MAC Member.

    "Rosacea is probably a collection of many different diseases that are lumped together inappropriately." Zoe Diana Draelos, MD. Dr. Draelos is a member of the ROSIE [ROSacea International Expert] Group that says the current classification of rosacea is controversial. Dr. Draelos is also a member of the RRDi MAC. Just because you have a red face might mean you have another skin condition besides rosacea.


    The ROSCO panel recommends a new approach diagnosising rosacea by phenotype. The RRDi has endorsed the ROSCO panel with this new classification of rosacea

    Rosacea Differentiation and Misdiagnosis

    Your physician should differentiate rosacea from a plethora of other skin conditions. If you need photos of rosacea click here.

    Sometimes rosacea is misdiagnosed. No one really knows what causes rosacea and there are a number of theories for your consideration. Our latest article on this subject, Rosacea Theories Revisited is worth the time. Rosacea, therefore, can be confusing, a bewilderment and a mystery

    Check our FAQs.

    What will the RRDi Do For Me?

    You can browse our member forum and learn about rosacea without joining. However, the RRDi is in the forefront of other rosacea non profit organizations with the digital medical revolution. Your rosacea is an individual case and you need to find what treatment will work for your rosacea and not a treatment aimed at the masses. Individuals can come together and share data, using collaboration tools that the RRDi offers for free. If you have the volunteer spirit and want to become part of this innovative non profit, learn how you can volunteer and be part of this digital medical revolution. You can post in our member forum if you join and register. If you have concerns regarding your privacy, please consider this post.

    Once you join you have a number of tools to collaborate with other members. You can create your own rosacea blog with our tools once you join, with easy step by step directions on how to do this. Our Gallery application lets members share photos and videos with the community. We have a chat tool available to members. Volunteers who contribute their time and energy may receive a free G Suite basic account through the generous contribution of Google, one of our sponsors.  

    For a limited time you may receive a free ebook, Rosacea 101: Includes the Rosacea Diet as a free gift from the founder/director if you mention in the application that you want the free ebook (write in the volunteer box).

    What Can You Do for the RRDi?

    Your joining and registering with our organization will increase our membership. Your generous donation will assist us to continue to keep this web site going, publish our journal, and sponsor education grants. Mahalo for your donation. even if it is small. Every dollar helps us keep going. 

    The RRDi is a volunteeer member driven organization and invites rosacea sufferers to become involved. Volunteering is the force that drives the organization and is an integral spirit of the RRDi philosophy. The RRDi warmly invites rosacea sufferers to participate in this non profit which you can become a part of. You are not required to volunteer when you join, since we still want you to join even if you can't volunteer. If all you can do is become a member, that will increase our membership which is helpful in itself. So if you can volunteer, let us know on the application. Please join. If you want to remain anonymous when becoming a member of the RRDi you may find it helpful to read this post before joining. We respect your anonymity and will support your remaining anonymous as a member of the RRDi if that is your preference. 

    However, we want real members, not spammers, hackers and trolls. So our membership registration is very secure requiring your contact information. Please carefully read the next subheading on how to join. 

    How to Join

    You may want to read our post about Anonymity, Transparency and Posting before joining which explains in a step by step process how to remain anonymous in our member forum. To post in our Member Forum or submit articles for publication you must register to join to become a member. The RRDi requires that you provide us with your contact info and mailing address and agree to our policies since you become a corporate member of the RRDi. Your privacy is our utmost concern and we will take precautions to ensure your privacy will not be violated. Our Privacy Policy is solid. If you have concerns regarding your privacy, please consider this post.

    Once you have joined you can post in our secure members forum which will allow you to post questions to the Medical Advisory Consultants (MAC) and to fellow members or to submit articles for our journal. Yes, members may have an article published on our web site or in our journal. You may receive a free G Suite account with our organization upon approval that you have the volunteer spirit. 


    The Charter of the Corporation states the purpose and Mission Statement which clearly outlines the goals of our non profit corporation. If you are interested in the history of how and why this non profit organization was formed click here for more information.  Mahalo. 

    The RRDi is registered at GuideStar

  • Recently Browsing   0 members

    No registered users viewing this page.

  • Member Statistics

    • Total Members
    • Most Online

    Newest Member
  • Forum Statistics

    • Total Topics
    • Total Posts
  • Who's Online (See full list)

    There are no registered users currently online

  • Posts

    • Tom Busby wrote this tip about washing off Soolantra:  "The base for Soolantra is Cetaphil Cream, according to the patents. This is not Cetaphil Lotion --- the Cream has a little petrolatum and as a result is slightly more occlusive, so it's slightly more difficult to wash off completely. You might find it useful to spend more time washing it off, or use the water stream of a shower to assist in washing it off. It's useful for general skin health to clean the skin completely at least once per day, and occlusive creams make this task a little more difficult. It may be useful for you to spend more time washing your face -- just an idea though. People with very dry skin like occlusive creams more than other people. Since you asked about comedogenic, I guess you don't have very dry skin. Here are the ingredients in the Cream, if it's any help -- the () comments are mine: Purified Water, Polyglycerylmethacrylate (hydrogel), Propylene Glycol (increases penetration), Petrolatum (long chain carbon-oil), Dicaprylyl Ether (emollient), PEG-5 Glyceryl Stearate (emulsifier and stabilizer), Glycerin (humectant), Dimethicone (silicone), Dimethiconol (silicone), Cetyl Alcohol (emulsifier), Sweet Almond Oil (medium chain carbon-oil), Acrylates/C10-30 Alkyl Acrylate Crosspolymer (hydrogel), Tocopheryl Acetate (synthetic Vitamin E), Phenoxyethanol (preservative), Benzyl Alcohol, Disodium EDTA (chelation), Sodium Hydroxide (activates 1st hydrogel by raising pH during the manufacturing process), Lactic Acid (lowers final pH) I speculate that the "1% line" in the ingredients comes after petrolatum, and that the petrolatum is about 1.5% to 2%.  Both silicones aren't soluble in oil or water, and they also make any cream more resistant to washing off." Rosacea Forum, Tom Busby, post #3  
    • "The FDA approval of RHOFADE™ exemplifies Allergan's commitment to continuing to address unmet patient needs through innovation in medical dermatology," said David Nicholson, Chief R&D Officer of Allergan plc. "We know persistent facial erythema associated with rosacea is a challenge for patients and physicians and having options can help in treating the disease. RHOFADE™ is the first and only alpha1A adrenoceptor agonist approved for persistent facial erythema associated with rosacea in adults. The FDA approval of RHOFADE™ represents a new prescription treatment that can effectively help physicians and their patients manage this condition."    Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults, Allegan Rhofade, also known as oxymetazoline hydrochloride cream (1 percent strength), is a topical cream made to treat persistent facial erythema (redness), as opposed to the other symptoms of rosacea, like easy flushing, red bumps and pus pimples, skin burning, and sensitivity, explains Joshua Zeichner, a New York City dermatologist.   FDA Approves Rhofade Rosacea Treatment, by Sarah Kinonenat, Allure The US Food and Drug Administration (FDA) has approved oxymetazoline hydrochloride 1% cream (Rhofade, Allergan) for the topical treatment of persistent facial erythema associated with rosacea in adults. Persistent facial erythema associated with rosacea is "a challenge for patients and physicians, and having options can help in treating the disease," David Nicholson, Allergan's head of research and development, said in a news release announcing approval. FDA OKs New Cream for Facial Erythema in Rosacea in Adults, Megan Brooks Medscape Rhofade, also known as oxymetazoline hydrochloride cream (1 percent strength), is a topical cream made to treat persistent facial erythema (redness), as opposed to the other symptoms of rosacea, like easy flushing, red bumps and pus pimples, skin burning, and sensitivity, explains Joshua Zeichner, a New York City dermatologist. How does Rhofade work? Rosacea sufferers experience an overactivity of blood vessels in the face, which is why those with rosacea flush easier than others. Over time, the persistent flushing can lead to what Zeichner likens to fixed background redness. "Rhofade directly addresses this redness by constricting the blood vessels," he explains.
    • DMT210 is a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea. PRNewswire According to the Dermata web site, "DMT210 has the potential to be the first topical treatment to reduce both the erythema and the inflammation (papules and pustules) of rosacea."
    • Related Articles Granulomatous & histiocytic dermatitides. Semin Diagn Pathol. 2016 Dec 14;: Authors: Wick MR Abstract
      Granulomas of the skin may be classified in several ways. They are either infectious or non-infectious in character, and they contain areas of necrobiosis or necrosis, or not. Responsible infectious agents may be mycobacterial, fungal, treponemal, or parasitic organisms, and each case of granulomatous dermatitis should be assessed histochemically for those microbes. In the non-infectious group, examples of necrobiotic or necrotizing granulomas include granuloma annulare; necrobiosis lipoidica; rheumatoid nodule; and lupus miliaris disseminates faciei. Non-necrobiotic/necrotizing and non-infectious lesions are exemplified by sarcoidosis; foreign-body reactions; Melkersson-Rosenthal syndrome; Blau syndrome; elastolytic granuloma; lichenoid and granulomatous dermatitis; interstitial granulomatous dermatitis; cutaneous involvement by Crohn disease; granulomatous rosacea; and granulomatous pigmented purpura. Histiocytic dermatitides that do not feature granuloma formation are peculiar reactions to infection, such as cutaneous malakoplakia; leishmaniasis; histoplasmosis; lepromatous leprosy; rhinoscleroma; lymphogranuloma venereum; and granuloma inguinale.
      PMID: 28094163 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles Successful Treatment of Rhinophyma With Fractionated Carbon Dioxide (CO2) Laser in an African-American Man: Case Report and Review of Literature of Fractionated CO2 Laser Treatment of Rhinophyma. J Drugs Dermatol. 2016 Nov 01;15(11):1465-1468 Authors: Kraeva E, Ho D, Jagdeo J Abstract
      Rhinophyma, a late complication of rosacea (phymatous subtype), is a chronic, progressive dermatological condition. The classic pre- sentation of rhinophyma is nodular, thickened skin over the distal nose, and is often accompanied by underlying erythema secondary to in ammation. Due to the unpleasant aesthetic and dis guring appearance, rhinophyma may be associated with a signi cant nega- tive psychosocial impact, resulting in decreased patient quality-of-life. Treatment of rhinophyma is challenging as topical and systemic pharmacotherapies have shown limited ef cacy. We present a case of a 39-year-old African-American male with long-standing, mild rhinophyma who was successfully treated with two sessions of fractionated carbon dioxide (CO2) laser. We also review the medical literature on fractionated CO2 laser treatment of rhinophyma. To the best of our knowledge, this is the rst report of successful treat- ment of rhinophyma using fractionated CO2 laser in an African-American man (Fitzpatrick VI). We believe that fractionated CO2 laser may be a safe and ef cacious treatment modality for rhinophyma in skin of color patients (Fitzpatrick IV-VI) and early intervention with fractionated CO2 laser to prevent rhinophyma worsening may yield better results than late intervention. <em>J Drugs Dermatol. 2016;15(11):1465-1468.</em>.
      PMID: 28095565 [PubMed - in process] {url} = URL to article